Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy tr...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

PrayTradeRepeat May. 13 at 2:44 PM

$CPIX DMD stands for Duchenne Muscular Dystrophy. It’s a rare genetic muscle-wasting disease that mostly affects boys. The body cannot properly produce dystrophin, a protein muscles need to protect and repair themselves. Over time, DMD weakens: • skeletal muscles • mobility and walking • breathing muscles • and eventually the heart Many patients later develop cardiomyopathy and heart failure, which is why cardiac-focused drugs matter. CPIX’s drug ifetroban is being studied in DMD because it may help reduce inflammation, fibrosis, and heart damage linked to the disease. Investors are excited because DMD is an orphan disease with: • huge unmet medical need • FDA incentives • possible accelerated approval pathways • and potentially massive commercial value if a therapy works So when traders discuss: • partnerships • buyouts • Phase 3 readiness • or accelerated approval …they’re asking whether ifetroban’s data could become strong enough to attract larger biotech or pharma companies.

0 · Reply

biotechdollars May. 13 at 1:06 PM

$CPIX frontiere...partnership or buyout depends on how strong DMD data is. Depends on phase 3 trial design. Depends on regulatory pathway, "accelerated approval" ot not. Depends on phase 3 requitements. IF great durable data then buyout, because multiple bidders. If good data, partnership. A phase 3 ready asset, provided phase 3 requirements are not onerous, would attract buyout bids. A buyout is preferred option for shareholders.

0 · Reply

integrityfirst May. 13 at 12:13 AM

$CPIX PTR SSC tough indication. However Earnings call made reference to "markets" and "populations". If a failure, can at least hope it tended to show anti fibrotic quality. This is not a technical story at this point. CPIX will live or die on its fundamentals. So my advice is to know the fundamentals. Your inquiry suggests you are attempting to do that.

0 · Reply

integrityfirst May. 13 at 12:08 AM

$CPIX

0 · Reply

PrayTradeRepeat May. 12 at 4:23 PM

$CPIX Holds up well against macro with 0.53 beta

0 · Reply

PrayTradeRepeat May. 12 at 3:30 PM

$CPIX Supply at 4.65 ?

0 · Reply

haha1978 May. 11 at 5:54 AM

$CPIX lets see if we test 5.10s this week.

0 · Reply

FranklinSaint9 May. 10 at 12:48 PM

$CPIX Undervalued microcap with existing revenue base.

0 · Reply

PrayTradeRepeat May. 10 at 3:31 AM

$CPIX Just going to hold till I wake up at 4:30AM to an 8K and 12.00 per share.

0 · Reply

PrayTradeRepeat May. 10 at 12:40 AM

$CPIX any expectations for SSC update?

0 · Reply

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

May 5, 2026, 4:30 PM EDT - 7 days ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 13 days ago

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

RDHL

Apr 28, 2026, 4:05 PM EDT - 14 days ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Apr 27, 2026, 8:00 AM EDT - 16 days ago

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

RDHL

2026-04-23T13:13:38.000Z - 20 days ago

Cumberland announces transaction to integrate commercial business with Apotex

Apr 23, 2026, 9:00 AM EDT - 20 days ago

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Apr 22, 2026, 8:00 AM EDT - 21 days ago

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

RDHL

2026-04-16T13:58:04.000Z - 27 days ago

Cumberland receives FDA approval for expanded Caldolor injection

Apr 16, 2026, 9:05 AM EDT - 27 days ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

2026-03-17T13:21:41.000Z - 2 months ago

Cumberland announces launch of new Sancuso website

Mar 17, 2026, 9:05 AM EDT - 2 months ago

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Mar 3, 2026, 5:00 PM EST - 2 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Mar 3, 2026, 4:30 PM EST - 2 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-02-25T12:20:11.000Z - 2 months ago

Cumberland and THI announce U.S. commercialization of Talicia

2026-02-25T12:17:19.000Z - 2 months ago

RedHill Biopharma announces full sales and operational launch of Talicia

RDHL

Feb 25, 2026, 7:00 AM EST - 2 months ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

RDHL

Feb 25, 2026, 7:00 AM EST - 2 months ago

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

Feb 24, 2026, 4:05 PM EST - 2 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

2026-02-04T14:11:54.000Z - 3 months ago

Cumberland receives fast track designation for DMD oral therapy from FDA

Feb 4, 2026, 9:05 AM EST - 3 months ago

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Dec 8, 2025, 9:05 AM EST - 5 months ago

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 5:00 PM EST - 6 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Nov 4, 2025, 4:30 PM EST - 6 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 28, 2025, 4:05 PM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

2025-10-20T13:05:16.000Z - 7 months ago

RedHill Biopharma signs strategic partnership with Cumberland

RDHL

Oct 20, 2025, 9:05 AM EDT - 7 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 7 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

2025-10-13T13:10:36.000Z - 7 months ago

Cumberland adds Vibativ to national group purchasing agreement with Premier

Oct 13, 2025, 9:05 AM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

2025-10-01T13:10:20.000Z - 8 months ago

Cumberland says ibuprofen injection product gets regulatory approval in Mexico

Oct 1, 2025, 9:05 AM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

2025-09-29T13:10:14.000Z - 8 months ago

Cumberland announces launch of Vibativ injection in Saudi Arabia

Sep 29, 2025, 9:05 AM EDT - 8 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 5, 2025, 4:30 PM EDT - 10 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

2025-08-04T13:10:32.000Z - 10 months ago

Cumberland announces availability of Vibativo 4-Vial Starter Pak through Vizient

Aug 4, 2025, 9:05 AM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

2025-06-23T17:50:52.000Z - 11 months ago

Cumberland shares latest results from its Phase 2 FIGHT DMD trial

Jun 23, 2025, 9:05 AM EDT - 11 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 1 year ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

2025-05-13T20:22:40.000Z - 1 year ago

Cumberland announces partnership with Qureight

May 13, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 1 year ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

2025-03-04T20:25:46.000Z - 1 year ago

Cumberland options imply 26.1% move in share price post-earnings

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

2025-02-18T12:39:36.000Z - 1 year ago

Cumberland announces NMPA approval of Vibativ injection in China

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

2025-02-04T12:36:58.000Z - 1 year ago

Cumberland reports ‘positive’ results from Phase 2 FIGHT DMD trial

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

2024-12-09T21:21:06.000Z - 1 year ago

Cumberland announces FDA approves sNDA for Acetadote product

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 7, 2024, 4:30 PM EDT - 2 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 2 years ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 7, 2023, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 8, 2023, 4:30 PM EDT - 3 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2023

Aug 8, 2023, 4:05 PM EDT - 3 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

PrayTradeRepeat May. 13 at 2:44 PM

0 · Reply

biotechdollars May. 13 at 1:06 PM

0 · Reply

integrityfirst May. 13 at 12:13 AM

0 · Reply

integrityfirst May. 13 at 12:08 AM

$CPIX

0 · Reply

PrayTradeRepeat May. 12 at 4:23 PM

$CPIX Holds up well against macro with 0.53 beta

0 · Reply

PrayTradeRepeat May. 12 at 3:30 PM

$CPIX Supply at 4.65 ?

0 · Reply

haha1978 May. 11 at 5:54 AM

$CPIX lets see if we test 5.10s this week.

0 · Reply

FranklinSaint9 May. 10 at 12:48 PM

$CPIX Undervalued microcap with existing revenue base.

0 · Reply

PrayTradeRepeat May. 10 at 3:31 AM

$CPIX Just going to hold till I wake up at 4:30AM to an 8K and 12.00 per share.

0 · Reply

PrayTradeRepeat May. 10 at 12:40 AM

$CPIX any expectations for SSC update?

0 · Reply

PrayTradeRepeat May. 8 at 12:40 AM

$CPIX

0 · Reply

PrayTradeRepeat May. 7 at 3:53 PM

$CPIX 4 HOUR The important part here is actually the structure: CPIX is still respecting the lower trendline still above the major 3.61 support still trying to hold above VWAP around 4.22-4.23 but volume is extremely weak Weak volume inside an ascending channel usually means: nobody is aggressively selling but nobody is aggressively buying either So this is basically drift/compression waiting for a catalyst. The real danger zone is if it loses: 4.22 VWAP then lower channel support around 4.15 because then you probably revisit 4.00 quickly But if volume suddenly expands and it breaks: 4.32 then 4.50 then 4.75 …you could get momentum back fast because the float is still small and this thing moves violently when volume comes in. Right now though? This is a waiting game candle.

0 · Reply

PrayTradeRepeat May. 7 at 3:03 PM

$CPIX Will be holding this for weeks most likely.

1 · Reply

haha1978 May. 7 at 1:10 PM

$CPIX cpix historically sold off last 3 Qs. 6 to 3 q3 and 5 to 2.80 Q4 and this one 4.70 to 4.25. Its fine. Earnings dont matter once the sale goes through.

1 · Reply

AIBioScanner May. 7 at 11:43 AM

$CPIX | AI-Based Findings on CPIX After running CPIX through my AI-driven quantitative framework, the stock is in a confirmed uptrend with sustained buying pressure above both key moving averages. CPIX is trading around $4.37, above both the 20-day (~$3.70) and 50-day (~$3.51) moving averages — indicating bullish momentum building from recent lows. Key signals: • Trading above both MAs — confirmed uptrend • MACD positive (+0.32) — bullish momentum • Range between ~$3.05 support and ~$4.92 resistance 1-Month Outlook: Base scenario: consolidation between $4.06–$4.68 Breakout above $4.92 could open a move toward $5.31 Breakdown below $3.05 may extend downside toward $2.81 Structure is bullish short-term. Watch for volume confirmation on any breakout. Not financial advice.

0 · Reply

PrayTradeRepeat May. 7 at 12:52 AM

$CPIX Was that shorting today or were people really selling ?

2 · Reply

stockphd May. 6 at 8:32 PM

$CPIX Ifetroban sounds like a good fit for long COVID as well luckily https://www.sciencedirect.com/science/article/pii/S2666354626000803

0 · Reply

PrayTradeRepeat May. 6 at 7:09 PM

$CPIX Shananigans

0 · Reply

PrayTradeRepeat May. 6 at 3:23 PM

$CPIX DAY / SWINGS : I would be careful building a plan around “guaranteed” recycling between 4.70 and 4.30 because once a stock spends this much time compressing under resistance, eventually one of two things usually happens: • it gets rejected hard again or • it finally breaks and squeezes fast Right now CPIX feels trapped between: • support around 4.25-4.35 • resistance around 4.70-4.75 The problem is the risk/reward changes depending on where you act. Selling into 4.70 resistance after repeated failures is logical trading. Chasing it there is dangerous. But assuming you’ll definitely get 4.26 back can become a trap if: • volume suddenly expands • biotech momentum returns intraday • shorts get squeezed • buyers finally accept price above 4.75 Then you’re watching it at 5.20 trying to decide whether to rebuy higher.

0 · Reply

PrayTradeRepeat May. 6 at 3:18 PM

$CPIX 4 HOUR & 1 HOUR The important thing is this: every time CPIX dips hard, it has not stayed down. That’s constructive. If this were truly broken, you’d expect weak bounces and lower highs all day long. Instead, it keeps reclaiming levels after ugly drops. At the same time, repeated failures at the same ceiling can eventually weaken a stock. So the next clean move probably needs: strong volume hold over VWAP and ideally a 15-minute candle that closes above the $4.70-$4.75 zone instead of just wicking through it Otherwise it stays trapped in this violent chop range where market makers shake everybody out both directions.

0 · Reply

haha1978 May. 6 at 2:32 PM

$CAPR $CADL $CPIX $SLS CADL is probably going to 9 or 12 next week to complete the cup and handle on the weekly with the updated P3 analysis that will hopefull prove that the cancer treatment is extra durable time wise. $XBI

2 · Reply

StocktwitsEarnings May. 6 at 10:15 AM

$CPIX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.22 down -375.00% YoY • Reported revenue of $9.13M down -22.04% YoY

0 · Reply

Market Cap	68.35M
Revenue (ttm)	44.52M
Net Income (ttm)	-2.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.38%
Debt to Equity Ratio	0.25

Volume	80,300
Avg Vol	1,197,202
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	62%
Beta	-0.06
Analysts	Strong Buy
Price Target	$8.50